NASDAQ:ULTI
Delisted
The Ultimate Software Group Stock News
$331.36
+0 (+0%)
At Close: Sep 17, 2019
Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology
11:47am, Tuesday, 11'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ClinicalTrials--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in
Ultimovacs ASA: First Quarter 2021 Result Presentation
02:05am, Tuesday, 11'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #1Q21--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 re
Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings
11:05am, Monday, 10'th May 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ASCO--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team wil
Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting
10:03am, Wednesday, 28'th Apr 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company's Phase I trial evaluating its universal cancer vaccine, UV1, in com
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
08:35am, Saturday, 10'th Apr 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #AACR2021--Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinic
OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical e
Ultimovacs ASA: Fourth Quarter 2020 Result Presentation
02:05am, Wednesday, 17'th Feb 2021
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #4Q20--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its fourth quarter 2021 r
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #DOVACC--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gyn
OSLO, Norway--(BUSINESS WIRE)---- $ULTI #Phase1--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced positive five-year Overall Survival (OS) data from the Phase I trial evaluating the company
